Autoimmune Gastrointestinal Dysmotility (AGID) Evaluation

Clinical Utility

January 2011

This then can help distinguish autoimmune GI dysmotility from chemotherapy side effects. Finally, a rising antibody titer in a previously seropositive patient can suggest cancer recurrence.

< Previous Slide

Clinical Utility

Next Slide >

 

Jump to section:

• Introduction
• New Profile
• Autoimmune Gastrointestinal Dysmotility
• Symptoms
• Diagnosis¹
• Autoimmune Gastrointestinal Dysmotility^1,2
• Gastrointestinal Motility Studies
• Antibody Evaluation
• Ganglionic Acetylcholine Receptor (AChR) Autoantibody^3,4
• Ganglionic Acetylcholine Receptor (AChR) Autoantibody
• Antibody Profile
• AGID Evaluation Testing Algorithm
• Clinical Utility
• Clinical Utility
• Summary
• References
• Questions?